Room: Humboldt-Professor for Chemistry, Pharmacology and Biomedical Informatics, Director of the Institute for Drug Development, Faculty of Medicine, University of Leipzig
since 01/2020 Humboldt Professor and Director of the Institute for Drug Development, Medical Faculty of the University of Leipzig
since 05/2005 Professor of Structural Biology and Chemistry, Vanderbilt University, Nashville, USA
09/2001 - 04/2005 Postdoctoral researcher at the University of Washington, Seattle, USA
09/1998 - 08/2001 Doctorate at the Goethe University, Frankfurt am Main
10/1994 - 08/1998 Study of chemistry, University Leipzig
Jens Meiler's research integrates innovative computational approaches for therapy design and drug discovery with experimental validation and optimization.
In particular, we develop and apply new algorithms for the generation and development of active pharmaceutical ingredients and so-called biologics, such as antibodies or vaccines. To do this, we use the Rosetta software suite (www.rosettacommons.org) and then use the algorithms for machine learning in the BioChemicalLibrary (BCL, www.meilerlab.org). We are collaborating with scientists around the world to apply these new algorithms to pressing human health challenges, including cancer, infectious diseases such as influenza or HIV, diseases that affect the brain such as schizophrenia or addiction, in cardiac arrhythmias or obesity. To effectively support the drug development cycle, the Institute for Drug Development is able to produce, characterize and test these compounds as well as biologics in-house. To enable our approach of rational, computational therapy design in the first place, we collaborate with others to determine the structure of critical human protein targets and pathogens using limited experimental data in silico.